Virometix develops fully synthetic vaccines against infectious diseases and cancer, including the anti-pneumococcal candidate V-212, now in Phase I. The USD 15 million round, provided by existing shareholders, will fund the next stage of clinical development.
- Announced on
- Round
- Undisclosed round
- Amount
- USD 15 M
- Location
- Schlieren, canton of Zurich
- Sector
- Biotech & life sciences
Investors
The investors were not named in the announcement.
Preparing a similar round?
The diagnostic shows you the instruments and investors that fit your stage.
Start the diagnostic